Core Viewpoint - Baoyi Pharmaceutical (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Group 1: Company Overview - Baoyi Pharmaceutical has developed China's first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential for low pre-storage antibodies and dosing frequency, targeting autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Group 2: Commercialization and Revenue Potential - Baoyi Pharmaceutical is transitioning from a pure research phase to commercialization, with its three core products already in various stages of commercialization, new drug application registration, or late-stage clinical trials [1] - According to a report from Xiniu Securities, Baoyi has established a clear commercialization model and timeline, with expectations that products will start contributing significantly to revenue by 2026, particularly KJ017 and SJ02 [1] - The KJ103 product, used for kidney transplant desensitization, is anticipated to start generating revenue from 2027, while other applications for KJ103 will contribute at later stages [1]
宝济药业-B再涨超10% 较招股价已涨近4.5倍 多款产品今年起将显著贡献收入